Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01392742
First received: July 11, 2011
Last updated: November 9, 2015
Last verified: November 2015

July 11, 2011
November 9, 2015
May 2011
July 2014   (final data collection date for primary outcome measure)
  • Percentage of Participants With Sustained Virological Response (SVR) [ Time Frame: 24 weeks after End of treatment (EOT) (up to Week 96) ] [ Designated as safety issue: No ]
    SVR was defined as undetectable Hepatitis C Virus Ribonucleic Acid (HCV RNA) 24 weeks after completion of the actual treatment period (a single last undetectable HCV RNA Polymerase Chain Reaction [PCR] measured greater than or equal to >=140 days post-treatment).
  • Percentage of Participants With Relapse [ Time Frame: Up to 24 weeks after EOT (up to Week 96) ] [ Designated as safety issue: No ]
    Relapse was define as аn undetectable HCV RNA during the treatment period, but without such during the follow-up.
  • Percentage of Participants Who Were Non-Responders [ Time Frame: Up to 24 weeks after EOT (up to Week 96) ] [ Designated as safety issue: No ]
    Non-responders were those participants who had not reached аn undetectable HCV RNA during the treatment period.
Correlation of sustained virological response (SVR: undetectable HCV RNA 24 weeks after end of treatment) with rapid and early virological response [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01392742 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With Positive Predictive Value on SVR at Week 4 [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
    Predictive value determined the relationship of the virological response at specified time to the total response. Positive predicted value= number of true positives/(number of true positives+ number of false positives). SVR was defined as undetectable HCV RNA 24 weeks after end of treatment. Percentage of participants who showed positive predictive value in treatment naive and those who failed previous treatment with interferon were reported.
  • Percentage of Participants With Positive Predictive Value on SVR at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Predictive value determined the relationship of the virological response at specified time to the total response. Positive predicted value= number of true positives/( number of true positives+ number of false positives). SVR was defined as undetectable HCV RNA 24 weeks after end of treatment. Percentage of participants who showed positive predictive value in treatment naive and those who failed previous treatment with interferon were reported.
  • Correlation of SVR With Rapid Virological Response (RVR) [ Time Frame: Up to 24 weeks after EOT (up to Week 96) ] [ Designated as safety issue: No ]
    Correlation of SVR with RVR was based on 3 symmetric measures; Kendall's tau-b, Kendall's tau-c and Gamma. SVR was defined as undetectable HCV RNA 24 weeks after end of treatment. RVR was defined as having undetectable HCV RNA 4 weeks after start of treatment.
  • Correlation of SVR With Early Virological Response (EVR) [ Time Frame: Up to 24 weeks after EOT (up to Week 96) ] [ Designated as safety issue: No ]
    Correlation of SVR with EVR was based on 3 symmetric measures; Kendall's tau-b, Kendall's tau-c and Gamma. SVR was defined as undetectable HCV RNA 24 weeks after end of treatment. EVR was defined as having undetectable HCV RNA 12 weeks after start of treatment.
  • Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response [ Time Frame: Week 4 and 12 ] [ Designated as safety issue: No ]
    Predictive value determined the relationship of host factors to virological response. Host factors included; RVR (EVR for Week 12), gender, liver fibrosis, HCV genotype, height and treatment duration for Week 4 after EOT excluding HCV genotype at Week 12 EOT. RVR was defined as having undetectable HCV RNA 4 weeks after start of treatment and EVR was defined as having undetectable HCV RNA 12 weeks after start of treatment.
  • Duration of Treatment in Participants With SVR by HCV Genotype [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    SVR was defined as undetectable HCV RNA 24 weeks after end of treatment.
  • Cumulative PEG-IFN Alfa-2a Dose in Participants With SVR by HCV Genotype [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    SVR was defined as undetectable HCV RNA 24 weeks after end of treatment.
  • Cumulative Ribavirin Dose in Participants With SVR by HCV Genotype [ Time Frame: Up to Week 72 ] [ Designated as safety issue: No ]
    SVR was defined as undetectable HCV RNA 24 weeks after end of treatment.
  • Percentage of Participants With Virological Response [ Time Frame: 4 weeks after EOT (up to Week 76) ] [ Designated as safety issue: No ]
    The Virological response at the end of treatment was defined as the percentage of participants with undetectable HCV RNA, HCV test (based on a single last undetectable HCV RNA PCR falling in the 4 weeks' time window at end of treatment), is basically the sum of participants with SVR and with relapse.
  • Correlation of baseline host factors and virological response (HCV RNA levels) [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Correlation of cumulative Pegasys/ribavirin dose and sustained virological response (SVR) [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
  • Relapse rate 24 weeks post-treatment [ Time Frame: approximately 4 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
This observational study will evaluate predictors of early on-treatment response and sustained virological response in patients with chronic hepatitis C receiving Pegasys (peginterferon alfa-2a) and ribavirin. Data will be collected from patients on treatment (24 or 48 weeks) and 24 weeks after the end of treatment.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients with chronic hepatitis C treated with Pegasys and ribavirin
Hepatitis C, Chronic
Not Provided
Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
443
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Serologically confirmed chronic hepatitis C (all genotypes)
  • Treatment with Pegasys and ribavirin according to the current standard of care and in line with current summaries of product characteristics (SPCs)/local labelling

Exclusion Criteria:

  • Coinfection with HIV and/or hepatitis B
  • Contraindications according to the SPC for Pegasys/ribavirin
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria
 
NCT01392742
ML25670
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP